IP Library Granted Patent US 11,179,468
Granted Patent B2
US 11,179,468 · App. 13/858,771 · Granted Nov 23, 2021

Fulvestrant formulations

Inventors: Bulusu Bhanu Teja (Hyderabad, IN); Nagesh R. Palepu (Southampton, PA)
Assignee: Eagle Pharmaceuticals, Inc.
A61K47/22A61K9/0019A61K31/565A61K47/10A61K47/14A61K47/20
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,179,468
App. No.
13/858,771
Granted
Nov 23, 2021
Kind
B2
Abstract

Long term storage stable fulvestrant-containing compositions are disclosed. The compositions can include fulvestrant; a solvent selected from dimethyl sulfoxide (DMSO), glycofurol, N-methyl pyrrolidone, and mixtures thereof; an oil mixture selected from a mixture of caprylic and capric triglycerides, a mixture of caprylic, capric and linoleic triglycerides, a mixture of caprylic, capric and succinic triglycerides, and a mixture of propylene glycol dicaprylate and propylene glycol dicaprate; and a sustained release member selected from benzyl benzoate, dihydrolipoic acid, benzyl alcohol and lipoic acid. The fulvestrant-containing compositions have less than about 5% total impurities, on a normalized peak area response (“PAR”) basis as determined by high performance liquid chromatography (“HPLC”) at a wavelength of 223 nm, after at least about 24 months of storage at a temperature of from about 5° C. to about 25° C.

Claims (45)

1. A fulvestrant-containing composition comprising:

a) fulvestrant from about 50 mg/ml to about 150 mg/ml;

b) a solvent selected from the group consisting of dimethyl sulfoxide (DMSO), glycofurol, and mixtures thereof;

c) an oil mixture of caprylic and capric triglycerides, said oil mixture containing about 50% to about 64% C 8 fatty acids and about 30% to about 45% C 10 fatty acids; and

d) benzyl benzoate as a sustained release member;

wherein said fulvestrant-containing composition is in the form of a solution having a long-term stability defined by less than about 5% total impurities after at least about 6 months of storage at a temperature of about 40° C.;

wherein said composition is substantially free of castor oil and castor oil derivatives; and

wherein the volume ratio of solvent:oil mixture:sustained release member is either (i) about 33%:about 25%:about 42%, or (ii) about 2:about 1:about 1 when the solvent is a two-solvent mixture.

2. The composition of claim 1 , wherein the solvent is DMSO.

3. The composition of claim 1 , wherein the solvent is a mixture of DMSO and glycofurol in a volume ratio of about 1:about 1.

4. The composition of claim 1 , wherein the fulvestrant concentration is from about 100 mg/ml to about 125 mg/ml.

5. The composition of claim 1 , wherein the fulvestrant concentration is about 50 mg/ml.

6. The composition of claim 4 , wherein the fulvestrant concentration is about 100 mg/ml.

7. The composition of claim 1 , having less than about 5% total impurities, on a normalized peak area response (“PAR”) basis as determined by high performance liquid chromatography (“HPLC”) at a wavelength of 223 nm, after at least about 36 months of storage at a temperature of from about 5° C. to about 25° C.

8. The composition of claim 1 , further comprising at least one antioxidant selected from the group consisting of lipoic acid, dihydrolipoic acid, methionine, sulpha-containing amino acids, acetone sodium bisulfate, propyl gallate, butylated hydroxytoluene (“BHT”), butylated hydroxyanisole (“BHA”) and sodium formaldehyde sulfoxylate.

9. A fulvestrant-containing composition comprising:

a) fulvestran from about 50 mg/ml to about 150 mg/ml;

b) DMSO;

c) a mixture of caprylic and capric triglycerides, said oil mixture containing about 50% to about 64% C 8 fatty acids and about 30% to about 45% C 10 fatty acids; and

d) benzyl benzoate;

wherein the DMSO is present in an amount of about 33% (v/v), the mixture of caprylic and capric triglycerides is present in an amount of about 25% (v/v), and the benzyl benzoate is present in an amount of about 42% (v/v);

said fulvestrant-containing composition being in the form of a solution having a long-term stability defined by less than about 5% total impurities after at least about 6 months of storage at a temperature of about 40° C.

10. The composition of claim 9 , having less than about 5% total impurities, on a normalized peak area response (“PAR”) basis as determined by high performance liquid chromatography (“HPLC”) at a wavelength of 223 nm, after at least about 36 months of storage at a temperature of from about 5° C. to about 25° C.

11. A fulvestrant-containing composition comprising:

a) fulvestrant from about 50 mg/ml to about 150 mg/ml;

b) DMSO;

c) a mixture of caprylic and capric triglycerides, said oil mixture containing about 50% to about 64% C 8 fatty acids and about 30% to about 45% C 10 fatty acids;

d) benzyl benzoate; and

e) glycofurol;

wherein the volume ratio of DMSO:mixture of caprylic and capric triglycerides:

benzyl benzoate:glycofurol is about 1:about 1:about 1:about 1;

said fulvestrant-containing composition is in the form of a solution having a long-term stability defined by less than about 5% total impurities after at least about 6 months of storage at a temperature of about 40° C.

12. The composition of claim 11 , having less than about 5% total impurities, on a normalized peak area response (“PAR”) basis as determined by high performance liquid chromatography (“HPLC”) at a wavelength of 223 nm, after at least about 36 months of storage at a temperature of from about 5° C. to about 25° C.

13. A liquid fulvestrant-containing composition consisting essentially of:

a) fulvestrant from about 50 mg/ml to about 150 mg/ml;

b) a solvent selected from the group consisting of dimethyl sulfoxide (DMSO), glycofurol, and mixtures thereof;

c) an oil mixture of caprylic and capric triglycerides, said oil mixture containing about 50% to about 64% C 8 fatty acids and about 30% to about 45% C 10 fatty acids; and

d) benzyl benzoate as a sustained release member;

wherein said fulvestrant-containing composition is in the form of a solution having a long-term stability defined by less than about 5% total impurities after at least about 6 months of storage at a temperature of about 40° C.;

wherein said composition is substantially free of castor oil and castor oil derivatives; and

wherein the volume ratio of solvent:oil mixture:sustained release member is either (i) about 33%:about 25%:about 42%, or (ii) about 2:about 1:about 1 when the solvent is a solvent mixture.

14. The composition of claim 1 , wherein the composition does not require refrigeration to maintain long-term stability.

15. The composition of claim 9 , wherein the composition does not require refrigeration to maintain long-term stability.

16. The composition of claim 11 , wherein the composition does not require refrigeration to maintain long-term stability.

17. The composition of claim 13 , wherein the composition does not require refrigeration to maintain long-term stability.

Assignments (7)
GRANT OF SECURITY INTEREST Recorded Feb 18, 2026
From: EAGLE PHARMACEUTICALS, INC
To: ANKURA TRUST COMPANY, LLC.
Reel/Frame 074849/0457 →
RELEASE OF SECURITY INTEREST Recorded Apr 1, 2025
From: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
To: EAGLE PHARMACEUTICALS, INC.
Reel/Frame 070703/0524 →
SECURITY INTEREST Recorded Oct 24, 2022
From: EAGLE PHARMACEUTICALS, INC.
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 061513/0804 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 27, 2018
From: HAZ TWO, LLC
To: EAGLE PHARMACEUTICALS, INC.
Reel/Frame 045658/0054 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 2, 2016
From: SCIDOSE, LLC
To: HAZ TWO, LLC
Reel/Frame 038786/0619 →
NUNC PRO TUNC ASSIGNMENT Recorded Jan 19, 2015
From: TEJA, BULUSU BHANU; PALEPU, NAGESH R.
To: SCIDOSE, LLC
Reel/Frame 034746/0378 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 12, 2013
From: TEJA, BULUSU BHANU; PALEPU, NAGESH R.
To: SCIDOSE, LLC
Reel/Frame 031207/0389 →
Continuity (2)
Provisional Application 61621785 · Apr 9, 2012
Related Publication 20130267489A1 · Oct 10, 2013